v3.26.1
Stockholders’ Equity
6 Months Ended
Jun. 30, 2026
Equity [Abstract]  
Stockholders’ Equity

Note 8 –Stockholders’ Equity

 

Omnibus Incentive Plan

 

Stock Options

 

Stock-based compensation expense is reflected in selling, general and administrative expenses in the accompanying condensed statements of operations and was $0.4 million and $1.4 million during the three months ended June 30, 2026 and 2025, respectively, and $0.9 million and $2.1 million during the six months ended June 30, 2026 and 2025, respectively. As of June 30, 2026, there was $1.7 million of unrecognized stock-based compensation expense related to outstanding stock options that will be recognized over the weighted average remaining vesting period of 1.36 years.

 

There were no options granted during the three and six months ended June 30, 2026. There were 17,142 options granted during the three and six months ended June 30, 2025 in connection with entering into certain employment and consulting agreements.

 

There were no options exercised during the three and six months ended June 30, 2026 and 2025.

 

There were 7,850 and 12,316 option grants forfeited during the three and six months ended June 30, 2026, respectively. There were 15,110 option grants forfeited during the three and six months ended June 30, 2025.

 

Warrants

 

There were no warrants issued or exercised during the three and six months ended June 30, 2026. Pre-funded warrants issued in 2023 and 2021 were exercised for 48,890 shares of common stock during the three and six months ended June 30, 2025 at an exercise price of $0.0001 per pre-funded warrant.

 

There were no warrants that expired during the three months ended June 30, 2026. There were warrants exercisable for 11,128 shares of common stock that expired during the three months ended June 30, 2025. There were warrants exercisable for 85,219 and 11,390 shares of common stock that expired during the six months ended June 30, 2026 and 2025, respectively.

 

Equity Issuances

 

There were approximately 17,000 shares of common stock issued during the three and six months ended June 30, 2026 under our at-the-market equity program resulting in proceeds of $0.1 million, net of transaction fees.